| miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and maydownregulate the high affinity cationic amino acid transporter CAT-1 J Chang, E Nicolas, D Marks, C Sander, A Lerro, MA Buendia, C Xu, ... RNA biology 1 (2), 106-113, 2004 | 1038 | 2004 |
| Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez, C Xu, K Rhee, ... Nature 534 (7605), 129-132, 2016 | 780 | 2016 |
| Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ... Cancer discovery 1 (1), 78-89, 2011 | 581 | 2011 |
| A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ... Nature 483 (7391), 613-617, 2012 | 497 | 2012 |
| Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β Y Lan, D Zhang, C Xu, KW Hance, B Marelli, J Qi, H Yu, G Qin, A Sircar, ... Science translational medicine 10 (424), eaan5488, 2018 | 439 | 2018 |
| Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections D Jiang, JM Weidner, M Qing, XB Pan, H Guo, C Xu, X Zhang, A Birk, ... Journal of virology 84 (16), 8332-8341, 2010 | 398 | 2010 |
| Loss of LKB1 and PTEN Lead to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression Cancer Cell 25 (5), 590, 2014 | 376 | 2014 |
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ... Cancer discovery 2 (10), 934-947, 2012 | 326 | 2012 |
| Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus D Jiang, H Guo, C Xu, J Chang, B Gu, L Wang, TM Block, JT Guo Journal of virology 82 (4), 1665-1678, 2008 | 319 | 2008 |
| EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors CM Fillmore, C Xu, PT Desai, JM Berry, SP Rowbotham, YJ Lin, H Zhang, ... Nature 520 (7546), 239-242, 2015 | 260 | 2015 |
| Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer EM Tricker, C Xu, S Uddin, M Capelletti, D Ercan, A Ogino, CA Pratilas, ... Cancer discovery 5 (9), 960-971, 2015 | 234 | 2015 |
| Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene Z Chen, T Sasaki, X Tan, J Carretero, T Shimamura, D Li, C Xu, Y Wang, ... Cancer research 70 (23), 9827-9836, 2010 | 232 | 2010 |
| Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR Q Liu, C Xu, S Kirubakaran, X Zhang, W Hur, Y Liu, NP Kwiatkowski, ... Cancer research 73 (8), 2574-2586, 2013 | 228 | 2013 |
| Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes F Liu, M Campagna, Y Qi, X Zhao, F Guo, C Xu, S Li, W Li, TM Block, ... PLoS pathogens 9 (9), e1003613, 2013 | 187 | 2013 |
| Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus C Xu, H Guo, XB Pan, R Mao, W Yu, X Xu, L Wei, J Chang, TM Block, ... Journal of virology 84 (18), 9332-9340, 2010 | 147 | 2010 |
| STING agonists induce an innate antiviral immune response against hepatitis B virus F Guo, Y Han, X Zhao, J Wang, F Liu, C Xu, L Wei, JD Jiang, TM Block, ... Antimicrobial agents and chemotherapy 59 (2), 1273-1281, 2015 | 143 | 2015 |
| Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer Y Liu, K Marks, GS Cowley, J Carretero, Q Liu, TJF Nieland, C Xu, ... Cancer discovery 3 (8), 870-879, 2013 | 142 | 2013 |
| Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET L Xu, E Kikuchi, C Xu, H Ebi, D Ercan, KA Cheng, R Padera, JA Engelman, ... Cancer research 72 (13), 3302-3311, 2012 | 129 | 2012 |
| Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition M Soucheray, M Capelletti, I Pulido, Y Kuang, CP Paweletz, JH Becker, ... Cancer research 75 (20), 4372-4383, 2015 | 118 | 2015 |
| Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion Y Lan, M Moustafa, M Knoll, C Xu, J Furkel, A Lazorchak, TL Yeung, ... Cancer cell 39 (10), 1388-1403. e10, 2021 | 106 | 2021 |
